Identification of a molecular signature predicting the relapse of tamoxifen-treated primary breast cancers should help the therapeutical management of ER-positive cancers.
Introduction
Breast cancer is the most common female cancer in the Western World and the leading cause of death by cancer among women. Although the mortality rate is now stabilized or decreasing, breast cancer incidence is still on the rise through all European countries [1] .
About two thirds of breast cancers are hormone (estrogen)-dependent as they are positive for estrogen receptor (ER) and/or progesterone receptor (PR). Estrogen being a major activator of proliferation in these tumors, its receptor and downsteam signaling are excellent targets for the hormonal therapy in patients with ER+ (and/or PR+) breast cancers. Over the past three decades, the anti-estrogen tamoxifen, which prevents the binding of estrogen to its receptor, has been the golden standard for the endocrine treatment of all stages of these cancers. In particular, large-scale randomized trials have shown that, in early stage ER+ breast cancers, a 5-year course of tamoxifen, started immediately after surgery, reduces recurrence by 51% and mortality by 28% [2] .
However, success of tamoxifen therapy is limited by intrinsic or acquired tumor resistance. Approximately 40% of patients with ER+ breast cancers will not respond to tamoxifen. This is mostly due to the fact that this selective estrogen receptor modulator is not a pure anti-estrogen and, indeed, shows some agonist activity. The balance between agonist and antagonist properties differs among cell types and seems to depend on several molecular events that can influence ER signaling. These include the level of co-activators and co-repressors and the impact of cross-signaling in growth factor transduction pathways [3] .
Recently, third-generation aromatase inhibitors (AIs) have been shown to be more effective than tamoxifen to treat both advanced and early hormone-sensitive breast cancers in menopausal women [4] . However, the absolute reduction in relapse-free survival for adjuvant AIs over tamoxifen is modest and the issue of long-term adverse effects in particular in bone, remains to be addressed. Moreover, AIs are also prone to develop resistance, although different mechanisms may be responsible for that.
As a consequence, the ability to accurately predict the response to tamoxifen should facilitate the choice of the best endocrine treatment and improve the management of primary ER+ breast cancers. Attempts to identify individual predictive markers failed to do that, so far. Recent publications on large-scale analysis of gene expression in HAL author manuscript inserm-00267736, version 1 breast cancers have underscored the considerable potential of DNA array technology.
Hierarchical clustering of gene expression patterns has been successfully used to identify subtypes of breast tumors that exhibit distinct clinical behaviors [5] [6] [7] [8] Supervised classifications of gene expression profiles have been performed to identify poor prognostic signatures, predictive of recurrence in primary breast cancers [9] [10] [11] .
Such analysis has been used to identify genes which can help to discriminate between responders and non-responders to chemotherapy agents in breast cancer [12, 13] .
Similar approaches have been tentatively used to define gene expression signatures that are predictive of recurrence in breast cancer patients treated with tamoxifen [14] [15] [16] . However, the study by Jansen et al. concerned metastatic breast cancers (i.e. the response to a recurrent disease) while that of Ma et al. reported a two-gene signature whose performance has been debated [17] [18] [19] . Both studies used a limited cohort of tumors as a training set (46 and 60 tumors, respectively). Finally, the study by Paik et al. defined a recurrence score predictor for lymph node-negative breast cancer [15] which also predicted the magnitude of chemotherapy benefit [20] . However, this classifier was constructed from 250 candidate genes that were previously selected from the published literature. Finally, several studies have also reported molecular prognostic signatures able to classify ER+ breast cancer whatever the patient treatment [21] [22] [23] [24] [25] .
In order to identify a gene expression signature that might predict recurrence of tamoxifen-treated primary breast cancers, we performed a genome-wide microarray analysis of ER+ and/or PR+ primary breast tumors from 132 patients, who had been treated with adjuvant tamoxifen. This analysis led to the identification of a 36-gene molecular signature that is highly predictive of clinical outcome.
Patients and methods

Patients and Treatment
132 primary breast carcinomas were analysed in this study as a training set and 23 extra tumors as a validation set ( Supplemental Table S1 ). These carcinomas were Fresh tissues were formalin-fixed and paraffin-embedded immediately after surgical removal. The remaining of each tumor was snap-frozen in liquid nitrogen and stored at -80° C. Frozen sections were stained with Haematoxylin and Eosin to select samples with at least 50% of tumor cells. ER and PR status were determined by using a radioligand binding assay or by immuno-histochemistry. All, but 8 tissue specimens, were ER+, and 6 out of the 8 ER-tumors were PR+.
None of the patients did receive neo-adjuvant systemic therapy. All patients were treated with tamoxifen (20 mg daily) for 5 years after surgery. 121 patients received also adjuvant radiotherapy. Recurrence was observed in 52 patients (48 distant metastases and 4 local recurrences) with median relapse time of 37.1 months. Tumors from those patients were defined as R tumors (R for relapse), whereas tumors from patients who showed no recurrence were defined as RF tumors (RF for relapse-free). For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion, TX, USA. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences, NJ, USA). Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. One-color design has been shown to be as performant as two-color design and it allowed easier normalization between samples [27] .
RNA Isolation, Amplification and Labeling
Microarray Gene Expression Analysis
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner (Molecular Devices, CA, USA) and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software.
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Gene expression signals were first normalized between arrays to the same median expression level (by dividing the intensity measurement for each gene on a given array by the median intensity of all genes across the array). Before analysis, a filter procedure eliminated non-informative genes on the basis of being significantly measured (i.e., expression level higher than two-fold the mean expression of the negative control spots in at least 40% of the samples). Then, we selected the 5,415 genes whose expression varied by at least three-fold from the median value in at least 1% of the samples. Expression data were then log-2 transformed.
The Significance Analysis of Microarrays (SAM) [28] was used to identify genes whose expression level best discriminated patients without (relapse-free, RF) and with relapse (R). This analysis was performed on the 132 tumors of the training set (86 RF and 46 R). A thousand permutations were generated to estimate the False Discovery Rate (FDR) value. Differences were considered as significant, when the FDR was less than 5% with a minimum 1.51 fold-change and when the SAM score was greater than (or equal to) ± 2.52.
A classifier that can predict recurrence under tamoxifen treatment was constructed by using the Prediction Analysis of Microarrays (PAM) [29] on the training set. A resampling approach was used, as described in van't Veer et al. [30] . As shown on Figure S1 (Supplementary data), the training set was splitted into 2 parts, a learning set (85 patients) and a test set (47 patients). The learning set was used to construct the classifier, while the test set was used to estimate its performance. The split procedure was repeated 100 times. For each learning set, a minimal molecular signature was estimated by a leave-one-out cross-validation and its performance was estimated by the average proportion of misclassification for each associated test set.
As the composition of the learning set changes in each iteration, the 100 minimal signatures obtained were obviously not identical. The final predictive signature corresponded to the most frequently selected genes (see results).
To confirm the molecular signature obtained by PAM, we used another classifier, the K-Nearest Neighbor (KNN) [31] with the same resampling of the training set.
A hierarchical pairwise average-linkage clustering [32] was performed on the basis of the expression of the signature genes with median centered gene expression values and Pearson correlation as similarity metric.
We classified the training set tumors according to the five subgroups defined by Sorlie et al. [7] on the basis of the highest correlation to the respective centroid as indicated in Supplementary Methods.
To evaluate the performance of the consensus predictive signature, we used 23 independent tumors (17 RF and 6 R) as an external validation set as well as gene expression data from the study of Ma et al. [14] . These data were obtained, like in our study, on 70-mer oligonucleotide microarrays and concerned 60 tamoxifen-treated patients (32 RF and 28 R). 41 patients ( Supplemental Table S2 ) belonged to the intermediate-risk group according to the St Gallen criteria [33] . Raw data were downloaded from GEO (http://www.ncbi.nlm.nih.gov/geo, accession number GSE1378). The Cy5 intensities were selected, normalized by median centering and log-2 transformed.
To compare the performance of the 36-gene signature with those of intrinsic subtype [7] , 70-gene profile [9] , wound-response [11] , two-gene ratio [34] , GGI [22] and MPI [24] , we evaluated the prognostic value of each expression-based model as indicated in Supplementary Methods, on both the training set (132 tumors) and a pooled validation set (83 tumors including the 23 tumors from our microarray study and the 60 tumors from the Ma's study).
Statistical analyses
Specificity, sensitivity and accuracy of the classifier as well as positive and negative predictive values were calculated as follows:
Sensitivity=A/(A+C); Specificity=D/(B+D); Accuracy=(A+D)/(A+B+C+D) 
Results
Identification of the differentially expressed genes
Patients were classified in two groups according to the occurrence of relapse (R) or its absence (relapse-free, RF) within the 5 years of tamoxifen treatment. To identify which genes were differentially expressed in R tumors versus RF, we used a SAM analysis of the 5,415 filtered genes (see Methods). Three hundred and one genes showed significant differences in their expression levels between R and RF tumors, with a false discovery rate below 5%. Then, the 48 most discriminating genes were selected on the basis of their fold-change and SAM score values ( Supplemental Table S3 ). Among those genes, 17 were overexpressed (positive SAM score) and 31 underexpressed (negative SAM score) in tumors from patients with relapse.
Determination of a 36-gene predictive signature
To define a minimal expression signature, which could be used as a molecular classifier to predict recurrence of tamoxifen-treated patients, gene expression data were analyzed using a PAM algorithm. We used the 5,415 filtered genes instead of the Supplemental Table S4 ). Since contracted signatures are favored for predictive tests in clinical practice, we selected the 36 genes, which were present in more than 60% of the 100 PAM iterative signatures, as the optimal molecular signature ( Table 1 ). This 36-gene signature classified the training set tumors with 80%
HAL author manuscript inserm-00267736, version 1 sensitivity, 78% specificity and 79% accuracy. The positive and negative predictive values of relapse were 87% and 68%, respectively.
Among the 36 signature genes, 26 belonged to the SAM selection of 48 genes (Table   1) , the remaining 10 genes coming out in the overall 301-gene list (not shown). A similar overlap between SAM and PAM analyses of expression data has been recently reported [36] .
To confirm the reliability of this signature, we used a KNN classifier. As for the PAM, a minimal predictive signature was defined for each iteration. The optimal consensus signature was obtained with 52 genes that were present in more than 47% of the 100 KNN iterative signatures ( Supplemental Table S4 ). According to this 52-gene signature, the training set was classified with 83% sensitivity, 74% specificity and 80% accuracy. Interestingly, 29 genes were common with those of the 36-gene PAM signature (Table 1) , thus, underlining the robustness of the 36-gene predictive signature.
We then performed hierarchical clustering of the 132 tumors of the training set based on the 36-genes signature. As shown in Figure 1 
Validation of the 36-gene predictive signature
The 36-gene predictive signature, as defined by the PAM analysis, was validated by an external set of 23 patients (6 R and 17 RF) that were enrolled independently.
Fourteen of the 17 RF (82% sensitivity) and 4 of the 6 R patients (67% specificity)
were correctly classified with a 78% accuracy.
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To confirm the performance of our classifier with a larger validation cohort, we used gene expression data obtained by Ma et al. on tamoxifen-treated patients [14] . We chose this data set as it was obtained on a 70-mer oligonucleotide microarray close to the one we used. We mapped our 36-genes signature on the Ma dataset by using Hugo gene symbols. Thirty-five out of the 36 signature-genes were available in this study (BC015719 was missing). The omission of this gene did not affect prediction of clinical outcome that was evaluated on our training set. The 60 independent tumors from the Ma cohort were classified with a 63% accuracy (69% sensitivity, 57% specificity), confirming the relevance of our classifier. (Table 2A) . Nevertheless, the predictive signature appeared to be the strongest predictive factor with 2 to 4-times higher odds ratios compared to other prognostic factors or indices. When performed on the validation set (83 patients), only the 36-gene signature and the NPI and Adjuvant! classifiers were found to be significant with almost similar odds ratios (Table 2B ).
Correlations to the clinical outcome
However, multivariate analysis that was performed both on the training and validation sets by using the parameters found to be significant in the univariate analysis, demonstrated that the 36-gene signature was the only independent prognostic factor (Table 2A and 2B).
Theses analyses confirmed that the molecular signature that we have identified was more efficient than the usual histo-pathological parameters to predict the clinical outcome of tamoxifen-treated breast cancers.
As shown on Figure 2 Table S1 and Table S2 ). This finding demonstrates that the 36-gene signature may be useful to discriminate patients of HAL author manuscript inserm-00267736, version 1 good and poor prognosis in this intermediate-risk group of patients to define the best therapeutical approach.
Comparison of the 36-gene signature with already published signatures
We have compared the performance of the present 36-gene signature with those of 6 gene-expression-based models that have been described for breast cancer, namely, intrinsic subtype, 70-gene profile, wound-response, two-gene ratio, gene expression grade index (GGI) and molecular prognostic index (MPI). confirmed the performance of the 36-gene signature that was as efficient as the twogene ratio to classify tumors (Table 3B ).
As shown on
Functional analysis of the predictive signature
With the exception of 1 EST and 4 genes with unknown function, all of the 36 genes appeared relevant to cancer (Table 1) . Indeed, the functional annotation showed that they were involved in the control of mitosis, cell cycle and cell proliferation, DNA replication and repair, cell signalisation, adhesion/migration, cell death/survival, ER transcriptional activity, immune response or metabolism.
Among these 36 genes, 23 were underexpressed and 13 were overexpressed in tumors from patients with recurrent disease in agreement with their putative function in oncogenesis. As shown in Table 4 , four of the underexpressed genes were involved in cellular adhesion or invasion, 3 could be implicated in immune response or inflammation and 2 others were putative negative regulators of ER. Moreover, 7 genes have been reported as candidate tumor suppressor genes (TSG), namely, AUTS2,
Among the upregulated genes, 7 were involved in the control of mitosis and cell cycle, has been demonstrated to be a key promoter of cellular invasion.
Interestingly, CX43 and ITM2B which have been proposed to have a pro-apoptotic function were down-regulated in tumors from recurrent patients while p15(PAF), which has been reported as a anti-apoptotic factor, was up-regulated in these tumors. Also, HAL author manuscript inserm-00267736, version 1 CX43, FMO5 and PCM1 have been reported as members of an apoptotic gene module whose overexpression specified low-grade ER+ breast tumors from patients with a better survival outcome [37] . All of them were found down-regulated in tumors from patients with relapse in this study.
Discussion
The main problem encountered in gene expression profiling studies is the relatively small overlap between independently reported molecular signatures. Noteworthy, the present 36-gene signature includes 11 genes (30%) that are members of a proliferation cluster present in several previously pulished classifiers. This major proliferation signature has been shown to specify poor-prognosis subsets of ER+ breast cancer [15, [21] [22] [23] [24] [25] . It includes AURKB, CCNB2, CDC2, PRC1, RRM2, TPX2
and UBE2C genes [22, 23] , which are present in our signature, along with BIRC5/survivin, KI-67, MYBL2, STK6/15, and CCNB1, belonging to the Paik's 21-gene classifier [15] . Several members of this proliferation gene cluster are also found in the van't Veer's 231-gene poor prognostic signature [9] , namely, BIRC5, CCNB2, PRC1, RRM2 and STK6/15. Another gene, TK1, is found to be a member of this cluster both in this and distinct studies [9, 21] . ASF1B [38] , ASPM [22, 38] and p15(PAF) [24, 39] have been also reported in proliferation gene clusters correlated to cancer aggressiveness [22, 38] .
Interestingly, similarity between these distinct gene signatures may further concern members of the same functional family or different partners of the same pathway(s).
For example, CCNB2 and AURKB (STK12) may be substituted by CCNB1 and AURKA (STK6/15), respectively. Moreover, AURKB interacts with survivin [40] and TPX2 targets AURKA to the mitotic spindle [41] .
Although the presence of such a proliferation cluster seems to be a hallmark of several prognostic signatures, the 11 members of this cluster from our 36-gene signature did not exhibit a prognostic power by itself (data not shown). This later finding demonstrates that the ER-related genes of the present signature could be essential to confer its prognostic power.
Indeed, our 36-gene signature included at least 18 genes (50%) that were related to estrogens either as ER targets or ER regulators. Six genes, namely CRIM1, CX43, FMO5, P37NB/LRRC17, STC2 and WFDC2 have been shown to be induced by HAL author manuscript inserm-00267736, version 1 estrogens and the expression of these genes has been correlated with ER+ status [42] [43] [44] . Interestingly, STC2 or FMO5 expression was associated with good prognosis in ER and/or PR+ breast cancer patients, who were treated with adjuvant hormone therapy [43, 44] . Conversely, TK1 overexpression, shown to occur in ER negative breast tumors [45] and in our cohort of R tumors, has been reported to be a marker of poor clinical outcome of tamoxifen therapy [46] . ABCC3 has been shown to be E2repressed [47] and was overexpressed in tumors from patients with recurrence. Eight other genes of the 36-gene signature (i.e., AURKB/STK12, CCNB2, CDC2, MMP1, PRC1, RRM2, TPX2 and UBE2C) have been reported to discriminate ER+ from ERbreast cancers [8, 23, 42] . Finally, 2 other genes, PNRC2 and PKIB, are possibly involved in the regulation of the ER activity. PNRC2 is mostly known to be a coactivator of nuclear receptors, including ER, and it has also been suggested to antagonize the growth factor-mediated MAP kinase activation of ER [48] . On the other hand, down-regulation of PKIB, a protein kinase A (PKA) inhibitor, might be associated with tamoxifen resistance. Indeed, such an association has been reported for PKAR1α, another PKA negative regulator whose down-regulation favored the phosphorylation of ER, converting tamoxifen from an ER antagonist into a growth stimulator [49] . Also, OTUD7B encodes a deubiquinating enzyme that has been demonstrated as a negative regulator of NFkappaΒ, a prognostic marker associated to tamoxifen resistance [50] .
In our study as in that by Paik et al. [15] , the classifiers were able to predict the clinical outcome of tamoxifen-treated breast cancers and thus they could be considered as general prognostic classifiers. Whether our 36-gene signature may further specify responsiveness to tamoxifen remains to be investigated. However, the presence of several estrogen-related genes in this signature suggests that it could be the case. In any case, this molecular signature allows to discriminate a subset of patients who do not gain benefits from tamoxifen treatment. Those patients might be potential Despite their value, expression signatures, which have been obtained by studying retrospective cohorts, need to be confirmed by prospective studies.
In summary, our findings demonstrate the utility of large-scale gene expression profiling to define a molecular signature that can predict the recurrence of tamoxifentreated primary breast cancer more efficiently than the usual clinical and histopathological prognostic factors. Moreover, our data bring new insights on putative master genes involved in cancer progression and resistance to endocrine therapy. Multivariate analysis was performed using the parameters found to be significant in univariate analysis. 
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